Brought to you by 
Neocrin options CellMart's cell growth technology
22 Sep 2004
Executive Summary
Neocrin Co. (diabetes treatments) acquired an option for exclusive worldwide rights to CellMart's (human cell expansion) cell proliferation technology to produce human islet cells for treating diabetes. The technology allows cells to grow and maintain normal physiology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neocrin options CellMart's cell growth technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice